A number of studies have shown that dysregulation of Shh ligand or one of its downstream mediators (Patched1, smoothened or Gli1) has been associated with urothelial carcinoma initiation and progression [23–25] and in regulating cancer stem cells activities [26]. Here, SHH is linked to cancer.